Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.

Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.

Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.

PSA might help diagnose PCOS and related skin issues, but more research is needed.

The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.

Testosterone therapy improves physical function, strength, and body composition in older men with low testosterone levels.

Low testosterone does not prevent prostate cancer in men with type 1 diabetes.

New treatments are making advanced prostate cancer management more complex but also more hopeful.

5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Early balding, especially frontal, increases prostate cancer risk; more research needed.

Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.

Men with less sun-sensitive skin have lower PSA levels, while men with more sun-sensitive skin have higher PSA levels.

The ABI1 gene contributes to prostate cancer progression and treatment resistance.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

The document suggests more research is needed to understand the link between baldness and prostate cancer.

Cardiac risk markers help assess heart risk in males with type 2 diabetes and low DHT.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Age, race, family history, and certain genetic factors increase prostate cancer risk.

Artocarpus heterophyllus seed extract may help treat prostate inflammation without side effects.

Physical activity, height, and smoking affect prostate cancer risk.

A49T gene variant linked to higher prostate cancer risk, lower hormone levels, and slightly reduced balding risk.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

The MATH+ protocol aims to improve COVID-19 outcomes using a combination of specific treatments.

Birth control pills increase certain receptor activities in female gerbil prostate glands and can lead to prostate changes.

Vitamin D may help regulate cholesterol and influence prostate cancer development.